^99mTc—MIBI显像预测乳腺癌新辅助化疗疗效的临床应用

目的 探讨^99mTc-MIBI显像预测乳腺癌新辅助化疗（NCT）疗效的临床价值.方法 50例局部进展期乳腺癌（LABC）患者化疗前行^99m Tc-MIBI显像,计算早期摄取比值（EUR）、晚期摄取比值（DUR）及清除率WR=（EUR-DUR）/EUR×100%].按照WHO制定的实体瘤疗效评定标准评价疗效,对化疗有效组及化疗无效组WR、EUR、DUR进行统计学比较.结果 化疗有效组与化疗无效组在WR、EUR、DUR值比较差异均有统计学意义（P＜0.05）.结论 ^99mTc-MIBI乳腺肿瘤显像中摄取与清除率WR在治疗有效组与无效组中均有统计学意义,肿瘤^99mTc-MIBI摄取越高,清除率越低,疗效越好,可有效预测LABC患者术前NCT疗效.

Clinical application of ^99mTc - MIBI imaging for the prediction of breast cancer response to neoadjuvant chemotherapy

Objective To discuss the clinical value of ^99mTc - MIBI imaging for the prediction of breast cancer to neoadjuvant chemotherapy （NCT）. Methods Fifty cases of locally advanced breast cancer （LABC） patients underwent ^99mTc - MIBI imaging, and the computational early uptake ratio （EUR）, delayed uptake ratio （DUR） and washout rate （ WR, % ） WR = （ EUR - DUR）/EUR x 100% ] were calculated. Clincial response was based on WHO criteria. WR, EUR, DUR of the effective chemotherapy group and ineffective chemotherapy group were statistically compared. Results WR , EUR and DUR were statistically significantly different （P 〈 0. 05 ） between effective chemotherapy group and ineffective chemotherapy group. Conclusion ^99mTc -MIBI breast tumor imaging uptake and washout rate in the treatment of effective group and ineffective groups have significant difference, the higher the tumor ^99mTc - MIBI uptake, washout rate is lower, the better the effect is, ^99mTc - MIBI breast tumor imaging can effectively predict the efficacy of NCT of LABC patients before operation.